Mode
Text Size
Log in / Sign up
N/A Completed N=15,873

Effectiveness and Tolerability of Tarka® in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus

Source: ClinicalTrials.gov NCT01079195 ↗
Enrolled (actual)
15,873
Serious AEs
0.1%
Results posted
May 2011
Primary outcomePrimary: Reduction in Systolic Blood Pressure and Diastolic Blood Pressure From Baseline to Study End — -28.5; -16.1 mmHg

Summary

The aim of this post-marketing observational study (PMOS) is to provide data on the effectiveness and tolerability of Tarka in patients with a high risk of developing diabetes mellitus, as prescribed by the physicians in a community setting and in accordance with the terms of the local marketing authorization. The following specific questions will be addressed: * Effectiveness of Tarka in lowering the blood pressure in hypertensive patients being at high risk of developing diabetes, not controlled on single-drug therapy. * Tolerability of Tarka as assessed by withdrawal rates.

Outcome Measures

OutcomeResultp-value
PRIMARY
Reduction in Systolic Blood Pressure and Diastolic Blood Pressure From Baseline to Study End
-28.5; -16.1 —
SECONDARY
Percentage of Participants Achieving Target Blood Pressure (Less Than 140/90) at Study End and the Need for Other Antihypertensive Drugs, Clustered by Type(s) of Drugs Added to Tarka.
68.1; 31.9; 74.6; 20.5; 1.1; 1.4 —
SECONDARY
Evaluation of Adverse Events (AEs) Leading to Discontinuation of Tarka and a Summary of All AEs Possibly or Probably Related to Tarka by Frequency and Severity
224; 199; 107; 82; 5; 5 —

Eligibility Criteria

Inclusion Criteria

  • Adult patients of either gender (more than 18 years of age), with established diagnosis of essential hypertension (systolic blood pressure/ diastolic blood pressure greater than 140/90 mmHg)
  • Patients not controlled on single-drug therapy and decision was made to introduce Tarka
  • Patients with a high risk of developing diabetes mellitus (defined according British Medical Society guidelines) with at least one of the following symptoms:
  • Positive family history of diabetes or
  • Obesity defined by a Body Mass Index (BMI) greater than 30 kg/m^2 or a waist circumference greater than 102 cm (males) or greater than 88 cm (females) or
  • Impaired fasting plasma glucose (FPG) levels of 6.1 to 7.0 mmol/l (100-126 mg/dl)

Exclusion Criteria

  • Patients with known or established Type 2 diabetes mellitus
  • The use of Tarka is contraindicated in the following patients:
  • Hypersensitive to the active substances or to any of the inactive ingredients
  • With cardiogenic shock
  • With second and third degree atrioventricular block - except in patients with a functioning artificial pacemaker
  • With sick sinus syndrome - except in patients with a functioning artificial pacemaker
  • With atrial fibrillation/flutter and concomitant Wolff-Parkinson-White syndrome
  • With existing history of angioedema associated with administration of an angiotensin-converting enzyme (ACE) inhibitor
  • With severe renal or severe liver impairment
  • In pregnant women (women of childbearing potential who are unwilling to use contraception should not be included)
  • Lactating women
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01079195). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search